Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

INTRODUCTION: Malignant mesothelioma (MM) is an aggressive disease with limited therapeutic options. In preclinical models, vascular endothelial growth factor (VEGF) stimulates MM proliferation. In MM patients, higher plasma VEGF levels correlate inversely with survival. Cediranib is an orally admin...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lung Cancer
Hoofdauteurs: Campbell, Nicholas P., Kunnavakkam, Rangesh, Leighl, Natasha, Vincent, Mark D., Gandara, David R., Koczywas, Marianna, Gitlitz, Barbara J., Agamah, Edem, Thomas, Sachdev P., Stadler, Walter M., Vokes, Everett E., Kindler, Hedy L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2012
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4319647/
https://ncbi.nlm.nih.gov/pubmed/22831987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.06.011
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items